Viral rebound uncommon after molnupiravir, nirmatrelvir-ritonavir therapy


Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec. 6 in JAMA Network Open.

Snag a Eufy RoboVac L35 Hybrid to handle the housework at its best price yet

Previous article

Half of U.S. adults not concerned about the flu

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations